Top 10 Private Equity Investors in Cancer Therapeutics & Diagnostics
| Rank | Investor Name |
|---|---|
| 1 | Casdin Capital |
| 2 | Ares Management |
| 3 | Bristol-Myers Squibb |
| 4 | Eli Lilly and Company |
| 5 | RA Capital Management |
| 6 | BB Biotech |
| 7 | GSK |
| 8 | Xoma |
| 9 | A&Z Pharmaceuticals |
| 10 | Logos Capital |
Oncology remains the deepest therapeutic category, driven by precision medicine and strategic pharma demand. These are buyers and control investors. This list is most relevant if you are selling the company, recapitalizing, or seeking a majority partner.
The CapitalDart directory identifies the right person to contact at each of these firms, with their individual investment criteria.
Create a free account and get the contacts for the investors above.
Rankings cover January 2025 to July 2026 investment activity in US and Canada companies. Seed and early-stage rankings measure deal participation, not suitability for every raise.